ClinicalTrials.gg
TerminatedNCT03918447FALCONUpdated Jun 3, 2025Results posted

A Trial of Bardoxolone Methyl in Patients With ADPKD - FALCON

A Phase 3 interventional study of Bardoxolone methyl oral capsule and Placebo oral capsule in Autosomal Dominant Polycystic Kidney and ADPKD, sponsored by Biogen. Terminated at 137 sites in 10 countries. Open to participants aged 12 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-06-03.

Sponsored by Biogen · Phase 3, Interventional, and Treatment

How we know

Why this study was terminated
Discontinuation of all bardoxolone chronic kidney disease programs

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
667
Allocation
Randomized
Ages
12 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 85 studies in Polycystic Kidney, Autosomal Dominant with a site in United States — 14 open to participants now, 25 under way, 1 of them phase 3. Polycystic Kidney, Autosomal Dominant · United States.

Enrollment
5th of 63
667 · median 48
Started
2019
with 4 others
Phase 3
13 of 85
none open now
Registered
50th of 85
by date
Lead sponsor
3 of 85
Biogen

Among the 85 studies in Polycystic Kidney, Autosomal Dominant with a site in United States, this one is the 5th largest by enrollment of the 63 interventional ones that give a count, is one of 5 that started in 2019, is one of 13 in phase 3, and was the 50th registered.

Polycystic Kidney, Autosomal Dominant

185 studies on the registry are indexed under Polycystic Kidney, Autosomal Dominant; 42 are open to participants now.

Browse Polycystic Kidney, Autosomal Dominant studies →

Open to participants now

14 of the 85 studies in Polycystic Kidney, Autosomal Dominant with a site in United States are open now. Recruiting first, the newest first:

9 more — sign in →

All 14 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 30 Polycystic Kidney, Autosomal Dominant studies recruiting now, 8 (27%) set no upper age limit and 19 (63%) stop at 75 or younger; 7 take children under 18; 9 take healthy volunteers.

This study: 12 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 85 studies in Polycystic Kidney, Autosomal Dominant with a site in United States, or all of them as a file.
02

Study summary

This international, multi-center, randomized, double-blind, placebo-controlled Phase 3 trial will study the safety, tolerability, and efficacy of bardoxolone methyl in qualified patients with ADPKD. Approximately 850 patients will be enrolled.

Read the detailed description

This international, multi-center, randomized, double-blind, placebo-controlled Phase 3 trial will study the safety, tolerability, and efficacy of bardoxolone methyl in qualified patients with ADPKD.

Patients will be randomized 1:1 to either bardoxolone methyl or placebo. Patients receiving bardoxolone methyl will start with once-daily dosing at 5 mg and will dose-escalate to 10 mg at Week 2, to 20 mg at Week 4, and then to 30 mg at Week 6 (only if baseline ACR >300 mg/g) unless contraindicated clinically and approved by the medical monitor. Dose de-escalation is permitted during the study if indicated clinically, and subsequent dose re-escalation is also permitted to meet the dosing objective of the highest tolerated dose.

All patients in the study will follow the same visit and assessment schedule. Patients will continue to receive study drug or placebo through Week 100 and will not receive study drug or placebo during a 12-week off-treatment period between Weeks 100 and 112.

03

Conditions studied

  • Autosomal Dominant Polycystic Kidney
  • ADPKD

Keywords

  • Bardoxolone Methyl
  • RTA 402
  • Autosomal Dominant Polycystic Kidney Disease
  • ADPKD
04

Who can participate

Ages eligible
12 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female patients 12 ≤ age ≤ 70 upon study consent;
  • Diagnosis of ADPKD by modified Pei-Ravine criteria (for adults 18≤ age ≤70 years): 1) at least 3 cysts per kidney by sonography or at least 5 cysts by CT or MRI with family history of ADPKD or 2) at least 10 cysts per kidney by any radiologic method and exclusion of other cystic kidney diseases if without family history;
  • Screening (average of Screen A and Screen B eGFR values) ≥ 30 to≤ 90 mL/min/1.73 m2 (12 to 55 years) or ≥ 30 to ≤ 44 mL/min/1.73 m2 (56 to 70 years):

    1. Patients with either screening eGFR ≥ 60 to ≤ 90 mL/min/1.73 m2 or age 56 to 70 years, must have evidence of ADPKD progression (i.e., eGFR decline of ≥ 2.0 mL/min/1.73 m2 per year, based on historical eGFR data and medical monitor discretion); 2)The two eGFR values collected at Screen A and Screen B visits used to determine eligibility must have a percent difference ≤ 25%;
  • Albumin to creatinine ratio (ACR) ≤ 2500 mg/g at Screen B visit;
  • Systolic blood pressure ≤ 140 mmHg and diastolic blood pressure ≤ 90 mmHg at Screen A or B visit after a period of rest.

Exclusion criteria

Exclusion Criteria:

  • History of administration of polycystic kidney disease-modifying agents (somatostatin analogues) within 2 months prior to the Screen A visit;
  • B-type natriuretic peptide (BNP) level > 200 pg/mL at Screen A visit;
  • Uncontrolled diabetes ( > 11.0%) at Screen A visit;
  • Serum albumin \< 3 g/dL at Screen A visit;
  • History of intracranial aneurysms;
  • Kidney or any other solid organ transplant recipient or a planned transplant during the study;
  • Acute dialysis or acute kidney injury within 12 weeks prior to Screen A visit or during Screening;
  • History of left-sided heart disease and/or clinically significant cardiac disease;
  • Systolic BP \< 90 mm Hg at Screen A visit after a period of rest;
  • \< 18.5 kg/m2 at the Screen A visit;
  • History of within 5 years prior to Screen A visit, with the exception of localized skin or cervical carcinomas;
  • Systemic for more than 2 weeks, cumulatively, within the 12 weeks prior to randomization or anticipated need for immunosuppression during the study;
  • Untreated or uncontrolled active bacterial, fungal, or viral infection;
  • Participation in other interventional clinical studies within 30 days prior to Day 1;
  • Unwilling to practice acceptable methods of (both males who have partners of and females of childbearing potential) during Screening, while taking study drug, and for at least 30 days after the last dose of study drug is ingested;
  • Women who are pregnant or breastfeeding;
  • Concomitant use of tolvaptan is excluded. Patients previously treated with tolvaptan must have discontinued drug for at least 2 months prior to Screen A visit
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
667 participants (actual)

Study arms

  • Experimental
    Maximum bardoxolone methyl dose of 20 mg

    Patients randomized to receive bardoxolone methyl with a baseline ACR less than or equal to 300 mg/g will be titrated to a maximum dose of 20 mg. Patients will begin once-daily dosing with bardoxolone methyl capsules at 5 mg and will dose escalate to 10 mg at Week 2 and 20 mg at Week 4. Patients will continue to receive study drug through Week 100, and will not receive study drug during a 12-week off-treatment period between Weeks 100 and 112.

    Drug: Bardoxolone methyl oral capsule

  • Experimental
    Maximum bardoxolone methyl dose 30 mg

    Patients randomized to receive bardoxolone methyl with a baseline ACR greater than 300 mg/g will be titrated to a maximum dose of 30 mg. Patients will begin once-daily dosing with bardoxolone methyl capsules at 5 mg and will dose escalate to 10 mg at Week 2, 20 mg at Week 4 and 30 mg at Week 6. Patients will continue to receive study drug through Week 100, and will not receive study drug during a 12-week off-treatment period between Weeks 100 and 112.

    Drug: Bardoxolone methyl oral capsule

  • Placebo comparator
    Placebo

    Patients randomized to placebo will remain on placebo capsules throughout the study, undergoing sham titration. Patients will continue to receive placebo capsules through Week 100, and will not receive capsules during a 12-week off-treatment period between Weeks 100 and 112.

    Drug: Placebo oral capsule

Interventions

  • DrugBardoxolone methylStudies of Bardoxolone methylBardoxolone methyl pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Bardoxolone methyl capsules dose escalated from 5 mg to a maximum of 20 or 30 mg, depending on baseline proteinuria status.

    Also known as: RTA 402

  • DrugPlacebo oral capsule

    Capsule containing an inert placebo

06

What researchers measure

Primary outcomes

  1. Off-treatment Period: Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) at Week 108

    Estimated Glomerular filtration rate (eGFR) is a measure of kidney function assessed through blood/serum. eGFR was measured in milliliters per minute per 1.73 meters square (mL/min/1.73 m\^2). Higher eGFRs represent better/improved kidney function. Lower eGFRs represent poorer/decreased kidney function. Negative change from baseline in eGFR indicates worsened kidney function.

    Time frame: Baseline, Week 108

  2. Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs

    AE:any untoward medical occurrence in a participant regardless of its causal relationship to study drug.AE can be any unfavorable \& unintended sign,symptom/disease temporally associated with use of study drug,whether considered to be study-drug related/not.This includes clinically significant abnormal laboratory test result,any newly occurring events/previous conditions that have increased in severity/frequency since administration of study drug. SAE:any AE that at any dose results in death,life-threatening,requires hospitalization/prolongation of existing hospitalisation,substantial disruption of ability to conduct normal life functions,congenital anomaly or is an important medical event. AEs \& SAEs that occurred during treatment and within 30 days after last dose were considered TE.

    Time frame: From first dose of the study drug up to end of follow-up (up to Week 112)

Secondary outcomes

  1. Treatment Period: Change From Baseline in eGFR at Week 100

    eGFR is a measure of kidney function assessed through blood/serum. eGFR was measured in mL/min/1.73 m\^2. Higher eGFRs represent better/improved kidney function. Lower eGFRs represent poorer/decreased kidney function. A negative change from baseline in eGFR indicates worsened kidney function.

    Time frame: Baseline, Week 100

07

Results

Posted Jun 11, 2024
Limitations and caveats
Due to discontinuation of all bardoxolone chronic kidney disease programs, study was terminated early.

Participant flow

Participants were enrolled at the investigative sites in the United States, Australia, Belgium, Czech Republic, France, Germany, Italy, Japan, Spain, and United Kingdom beginning on 29 May 2019. The study completion date was 8 August 2023.

Participant flow — Overall Study
MilestoneBardoxolone MethylPlacebo
Started334333
Safety analysis set335331
Completed106112
Not completed228221
Withdrew: Death10
Withdrew: Lost to follow-up136
Withdrew: Withdrawal by subject1917
Withdrew: Study terminated by sponsor195197
Withdrew: Reason not specified01

Outcome measures

PrimaryOff-treatment Period: Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) at Week 108

Estimated Glomerular filtration rate (eGFR) is a measure of kidney function assessed through blood/serum. eGFR was measured in milliliters per minute per 1.73 meters square (mL/min/1.73 m\^2). Higher eGFRs represent better/improved kidney function. Lower eGFRs represent poorer/decreased kidney function. Negative change from baseline in eGFR indicates worsened kidney function.

Time frame:
Baseline, Week 108
Reported as:
Least squares mean · mL/min/1.73 m^2
Off-treatment Period: Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) at Week 108
mL/min/1.73 m^2Bardoxolone MethylPlacebo
Off-treatment Period: Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) at Week 108-4.59 ± 0.817-5.56 ± 0.769
Statistical analysis
  • Bardoxolone Methyl vs Placebo · ANCOVA · p = =0.3886 · Least square means difference: 0.97 · 95% CI -1.25 to 3.19
PrimaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs

AE:any untoward medical occurrence in a participant regardless of its causal relationship to study drug.AE can be any unfavorable \& unintended sign,symptom/disease temporally associated with use of study drug,whether considered to be study-drug related/not.This includes clinically significant abnormal laboratory test result,any newly occurring events/previous conditions that have increased in severity/frequency since administration of study drug. SAE:any AE that at any dose results in death,life-threatening,requires hospitalization/prolongation of existing hospitalisation,substantial disruption of ability to conduct normal life functions,congenital anomaly or is an important medical event. AEs \& SAEs that occurred during treatment and within 30 days after last dose were considered TE.

Time frame:
From first dose of the study drug up to end of follow-up (up to Week 112)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs
ParticipantsBardoxolone MethylPlacebo
TEAEs314296
Serious TEAEs3826
SecondaryTreatment Period: Change From Baseline in eGFR at Week 100

eGFR is a measure of kidney function assessed through blood/serum. eGFR was measured in mL/min/1.73 m\^2. Higher eGFRs represent better/improved kidney function. Lower eGFRs represent poorer/decreased kidney function. A negative change from baseline in eGFR indicates worsened kidney function.

Time frame:
Baseline, Week 100
Reported as:
Least squares mean · mL/min/1.73 m^2
Treatment Period: Change From Baseline in eGFR at Week 100
mL/min/1.73 m^2Bardoxolone MethylPlacebo
Treatment Period: Change From Baseline in eGFR at Week 1001.31 ± 0.550-6.64 ± 0.549
Statistical analysis
  • Bardoxolone Methyl vs Placebo · MMRM · p = <0.0001 · Least square means difference: 7.94 · 95% CI 6.41 to 9.47

Adverse events

Collected over From first dose of the study drug up to end of follow-up (up to Week 112). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Bardoxolone Methyl1/335 (0.3%)38/335 (11.3%)299/335 (89.3%)
Placebo0/331 (0%)26/331 (7.9%)255/331 (77%)
Most frequent serious events
Showing 10 of 74
Most frequent serious events
EventBardoxolone MethylPlacebo
Hepatic enzyme increasedInvestigations3/3350/331
Renal cyst rupturedRenal and urinary disorders3/3350/331
PyelonephritisInfections and infestations2/3352/331
Renal cyst infectionInfections and infestations2/3352/331
Retinal detachmentEye disorders2/3350/331
Pneumonia viralInfections and infestations2/3350/331
SepsisInfections and infestations2/3350/331
ObesityMetabolism and nutrition disorders2/3350/331
Splenic cystBlood and lymphatic system disorders0/3351/331
Inguinal herniaGastrointestinal disorders0/3351/331
Most frequent other events
Showing 10 of 34
Most frequent other events
EventBardoxolone MethylPlacebo
Muscle spasmsMusculoskeletal and connective tissue disorders164/33553/331
Corona virus infectionInfections and infestations76/33589/331
Alanine aminotransferase increasedInvestigations76/3353/331
HeadacheNervous system disorders55/33541/331
NauseaGastrointestinal disorders49/33540/331
FatigueGeneral disorders47/33529/331
Aspartate aminotransferase increasedInvestigations47/3354/331
Hepatic enzyme increasedInvestigations46/3351/331
Flank painMusculoskeletal and connective tissue disorders43/33521/331
NasopharyngitisInfections and infestations39/33531/331

Baseline characteristics

Intent-to-Treat (ITT) population included all enrolled participants categorized by their randomized treatment group (whether or not they received study drug).

Age, Continuous
Age, Continuous(years)Bardoxolone MethylPlaceboTotal
Mean48.6 ± 9.4648.3 ± 9.5848.4 ± 9.51
Sex: Female, Male
Sex: Female, Male(Participants)Bardoxolone MethylPlaceboTotal
Female188173361
Male146160306
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Bardoxolone MethylPlaceboTotal
Hispanic or Latino293564
Not Hispanic or Latino305298603
Unknown or Not Reported000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Bardoxolone MethylPlaceboTotal
Race — American Indian or Alaska Native112
Race — Asian344579
Race — Black or African American231841
Race — Native Hawaiian or Other Pacific Islander101
Race — White269261530
Race — Other6814
08

Study locations

137 sites
  • University of Alabama at Birmingham
    Birmingham, Alabama 35294, United States
  • Nephrology Associates PC
    Homewood, Alabama 35209, United States
  • Nephrology Consultants, LLC
    Huntsville, Alabama 35805, United States
  • AKDHC
    Glendale, Arizona 85306, United States
  • Aventiv Research, Inc
    Mesa, Arizona 85210, United States
  • University of Arizona
    Tucson, Arizona 85719, United States
  • Rancho Research Institute
    Downey, California 90242, United States
  • California Institute Renal Research
    La Mesa, California 91942, United States
  • University of California, Los Angeles
    Los Angeles, California 90025, United States
  • Keck USC/LAC
    Los Angeles, California 90033, United States
  • Amicis Research Center
    Northridge, California 91324, United States
  • Stanford University
    Palo Alto, California 94304, United States
  • Apex Research of Riverside
    Riverside, California 92505, United States
  • University of California San Francisco
    San Francisco, California 94143, United States
  • Western Nephrology
    Arvada, Colorado 80002, United States
  • University of Colorado Anschutz Medical Center
    Aurora, Colorado 80045, United States
  • Kidney Associates of Colorado
    Denver, Colorado 80210, United States
  • Denver Nephrologist, PC
    Denver, Colorado 80230, United States
  • Western Nephrology and Mineral Bone Disease, PC
    Westminster, Colorado 80031, United States
  • Yale University School of Medicine
    New Haven, Connecticut 06520, United States
  • Pro-Care Research Center, Corp.
    Miami Gardens, Florida 33014, United States
  • University of Miami
    Miami, Florida 33136, United States
  • Discovery Medical Research Group
    Ocala, Florida 34471, United States
  • Innovation Medical Research Center, Inc
    Palmetto Bay, Florida 33157, United States
  • Volunteer Medical Research
    Port Charlotte, Florida 33952, United States
  • University of South Florida
    Tampa, Florida 33606, United States
  • Florida Premier Research Institute, LLC
    Winter Park, Florida 32789, United States
  • Emory University
    Atlanta, Georgia 30322, United States
  • Georgia Nephrology, LLC
    Lawrenceville, Georgia 30046, United States
  • Boise Kidney & Hypertension, PLLC
    Caldwell, Idaho 83605, United States
  • Boise Kidney & Hypertension, PLLC
    Meridian, Idaho 83642, United States
  • Northwestern University
    Chicago, Illinois 60611, United States
  • University of Chicago
    Chicago, Illinois 60617, United States
  • Loyola University Chicago
    Maywood, Illinois 60153, United States
  • University of Kansas Medical Center
    Kansas City, Kansas 66224, United States
  • Cotton O'Neil Clinical Research Center
    Topeka, Kansas 66606, United States
  • Ascension Via Christi Research
    Wichita, Kansas 67214, United States
  • Kansas Nephrology Research Institute, LLC
    Wichita, Kansas 67214, United States
  • Renal Associates of Baton Rouge
    Baton Rouge, Louisiana 70808, United States
  • Northwest Louisiana Nephrology
    Shreveport, Louisiana 71101, United States
  • University of Maryland School of Medicine
    Baltimore, Maryland 21201, United States
  • The Johns Hopkins University
    Baltimore, Maryland 21287, United States
  • Tufts Medical Center
    Boston, Massachusetts 02111, United States
  • Beth Israel Deaconess Medical Center
    Boston, Massachusetts 02215, United States
  • KidneyCare and Tranplant Services of New England
    Springfield, Massachusetts 01104, United States
  • Renal and Transplant Associates of New England, PC
    Springfield, Massachusetts 01107, United States
  • Paragon Health PC d/b/a Nephrology Center PC
    Kalamazoo, Michigan 49007, United States
  • Michigan Kidney Consultants
    Pontiac, Michigan 48341, United States
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
  • Clinical Research Consultants, LLC
    Kansas City, Missouri 64111, United States
  • Washington University in St. Louis
    Saint Louis, Missouri 63110, United States
  • KSOSN
    Las Vegas, Nevada 89129, United States
  • Nephrology Associates, P.C.
    Flushing, New York 11355, United States
  • Division of Kidney Diseases and Hypertension
    Great Neck, New York 11021, United States
  • NYU Winthrop Hospital
    Mineola, New York 11501, United States
  • Mountain Kidney & Hypertension Associates
    Asheville, North Carolina 28801, United States
  • Metrolina Nephrology Associates
    Charlotte, North Carolina 28204, United States
  • North Carolina Nephrology, P.A. 2nd Floor
    Raleigh, North Carolina 27609, United States
  • Brookview Hills Research Associates, LLC
    Winston-Salem, North Carolina 27103, United States
  • Cincinnati VA Medical Center
    Cincinnati, Ohio 45220, United States
  • University of Cincinnati College of Medicine
    Cincinnati, Ohio 45267, United States
  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
  • Remington-Davis Clinical Research
    Columbus, Ohio 43215, United States
  • Northeast Clinical Research Center
    Bethlehem, Pennsylvania 18017, United States
  • University of Pennsylvania
    Philadelphia, Pennsylvania 19014, United States
  • Children's Hospital of Philadelphia
    Philadelphia, Pennsylvania 19104, United States
  • Columbia Nephrology Associates, PA
    Columbia, South Carolina 29203, United States
  • Nephrology Associates, P.C.
    Nashville, Tennessee 37205, United States
  • TTUHSC
    Amarillo, Texas 79106, United States
  • Arlington Nephrology, PA
    Arlington, Texas 76015, United States
  • Research Management, Inc.
    Austin, Texas 78751, United States
  • Research Management, Inc.
    Austin, Texas 78758, United States
  • Liberty Research Center
    Dallas, Texas 75230, United States
  • Renal Disease Research Institute
    Dallas, Texas 75235, United States
  • Davita Clinical Research
    El Paso, Texas 79925, United States
  • DaVita Med Center
    Houston, Texas 77004, United States
  • Clinical Advancement Center
    San Antonio, Texas 78215, United States
  • University of Vermont Medical Center
    Burlington, Vermont 05401, United States
  • University of Virginia
    Charlottesville, Virginia 22908, United States
  • Nephrology Associates of Northern Virginia, Inc.
    Fairfax, Virginia 22033, United States
  • Swedish Medical Center
    Seattle, Washington 98052, United States
  • Medical College of Wisconsin
    Milwaukee, Wisconsin 53226, United States
  • Milwaukee Nephrologists, SC
    Wauwatosa, Wisconsin 53226, United States
  • Renal Research
    Gosford, New South Wales 2250, Australia
  • John Hunter Hospital
    New Lambton, New South Wales 2305, Australia
  • Westmead Hospital
    Sydney, New South Wales 2145, Australia
  • Sunshine Coast University Hospital
    Birtinya, Queensland 4575, Australia
  • Royal Brisbane and Women's Hospital
    Herston, Queensland 4029, Australia
  • Royal Adelaide Hospital
    Adelaide, South Australia 5000, Australia
  • Monash Health
    Clayton, Victoria 3168, Australia
  • Melbourne Health
    Parkville, Victoria 3050, Australia
  • Melbourne Renal Research Group
    Reservoir, Victoria 3073, Australia
  • Fiona Stanley Hospital
    Murdoch, Western Australia 6150, Australia
  • Nephrology, Cliniques U St-Luc
    Brussels, 1200, Belgium
  • Universitair Ziekenhuis Brussel (VUB)
    Brussels, B-1090, Belgium
  • University Hospitals Leuven, Dept. of Nephrology, Dialysis and Renal Transplantation
    Leuven, 3000, Belgium
  • Chu Liege
    Liège, 4000, Belgium
  • FN Brno
    Brno, 62500, Czechia
  • Nephrology Dept., General Teaching Hospital
    Prague, 12808, Czechia
  • IKEM
    Praha, 14021, Czechia

Showing the first 100 of 137 sites across 10 countries. Choose a country and city above to see the rest.

09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — In accordance with Biogen's Clinical Trial Transparency and Data Sharing Policy on https://www.biogentrialtransparency.com/

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2019 to primary completion in Aug 2023, 50 months.

Results were first posted in Jun 2024, 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 12, 2019
First posted
Apr 17, 2019
StartActual
May 29, 2019
Primary completionActual
Aug 8, 2023
CompletionActual
Aug 8, 2023
Results first posted
Jun 11, 2024
Last update
Jun 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03918447
Lead sponsor
Biogen
Responsible party
Sponsor
First posted
Apr 17, 2019
Start date
May 29, 2019
Primary completion
Aug 8, 2023
Completion
Aug 8, 2023
Results posted
Jun 11, 2024
Last update
Jun 3, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bardoxolone methyl

Start the discussion